company background image
RDHL

RedHill Biopharma NasdaqGM:RDHL Stock Report

Last Price

US$0.22

Market Cap

US$19.3m

7D

-38.6%

1Y

-93.0%

Updated

08 Dec, 2022

Data

Company Financials +
RDHL fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

RDHL Stock Overview

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.

RedHill Biopharma Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for RedHill Biopharma
Historical stock prices
Current Share PriceUS$0.22
52 Week HighUS$3.32
52 Week LowUS$0.21
Beta1.97
1 Month Change-63.87%
3 Month Change-74.79%
1 Year Change-92.96%
3 Year Change-96.36%
5 Year Change-95.33%
Change since IPO-97.98%

Recent News & Updates

One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts

Nov 24
One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts

Recent updates

One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts

Nov 24
One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts

RedHill Biopharma Ltd. (NASDAQ:RDHL) Just Reported, And Analysts Assigned A US$15.79 Price Target

Dec 02
RedHill Biopharma Ltd. (NASDAQ:RDHL) Just Reported, And Analysts Assigned A US$15.79 Price Target

Shareholder Returns

RDHLUS PharmaceuticalsUS Market
7D-38.6%-0.3%-2.8%
1Y-93.0%14.1%-19.6%

Return vs Industry: RDHL underperformed the US Pharmaceuticals industry which returned 13.4% over the past year.

Return vs Market: RDHL underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is RDHL's price volatile compared to industry and market?
RDHL volatility
RDHL Average Weekly Movement20.7%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: RDHL is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: RDHL's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2009201Dror Ben-Asherhttps://www.redhillbio.com

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study.

RedHill Biopharma Ltd. Fundamentals Summary

How do RedHill Biopharma's earnings and revenue compare to its market cap?
RDHL fundamental statistics
Market CapUS$19.31m
Earnings (TTM)-US$92.31m
Revenue (TTM)US$71.07m

0.3x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RDHL income statement (TTM)
RevenueUS$71.07m
Cost of RevenueUS$35.17m
Gross ProfitUS$35.90m
Other ExpensesUS$128.21m
Earnings-US$92.31m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.07
Gross Margin50.51%
Net Profit Margin-129.88%
Debt/Equity Ratio-247.4%

How did RDHL perform over the long term?

See historical performance and comparison